000157961 000__ 01333fam\a2200313\a\4500
000157961 001__ 157961
000157961 005__ 20220217103341.0
000157961 007__ he-bmb024bbca
000157961 008__ 921028s1992\\\\mdua\\\\b\\\\f100\0\eng\d
000157961 035__ $$a(OCoLC)ocm26873798
000157961 035__ $$9(IS)TVS8287
000157961 035__ $$9AAS4772SI
000157961 035__ $$a157961
000157961 040__ $$aGPO$$cGPO
000157961 043__ $$an-us---
000157961 049__ $$aISUW
000157961 074__ $$a0507-G-02 (MF)
000157961 0860_ $$aHE 20.3152:W 89/3
000157961 1102_ $$aNational Cancer Institute (U.S.).$$bCancer Therapy Evaluation Program.$$bInvestigational Drug Branch.$$bPhase I Working Group.$$bMeeting$$d(1990 :$$cBethesda, Md.)
000157961 24510 $$aMinutes of the Phase I Working Group$$h[microform] :$$bOctober 9-11, 1990.
000157961 260__ $$aBethesda, Md. :$$bInvestigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute,$$c[1992?]
000157961 300__ $$aviii, 261 p. :$$bill. ;$$c28 cm.
000157961 500__ $$aDistributed to depository libraries in microfiche.
000157961 500__ $$aShipping list no.: 92-2051-M.
000157961 533__ $$aMicrofiche.$$b[Washington, D.C.?] :$$cSupt. of Docs., U.S. G.P.O.,$$d[1992]$$e5 microfiches : negative.
000157961 650_0 $$aDrugs$$zUnited States$$xTesting$$vCongresses.
000157961 650_0 $$aCancer$$zUnited States$$xChemotherapy$$vCongresses.
000157961 7102_ $$aNational Cancer Institute (U.S.).$$bCancer Therapy Evaluation Program.$$bInvestigational Drug Branch.
000157961 85230 $$bdfich$$hHE 20.3152:$$iW 89/3
000157961 909CO $$ooai:library.usi.edu:157961$$pGLOBAL_SET
000157961 948__ $$ac:pw
000157961 980__ $$aBIB
000157961 980__ $$aGOV RESOURCE